VIMPAT® is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).
SELECT IMPORTANT SAFETY INFORMATION
VIMPAT is associated with important warnings and precautions including suicidal behavior and ideation, dizziness and ataxia, cardiac rhythm and conduction abnormalities, syncope, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi-organ hypersensitivity.
In the adult monotherapy clinical trial, adverse reactions were generally similar to those observed and attributed to drug in adjunctive placebo-controlled trials, with the exception of insomnia (observed at a higher rate of ≥2%). In the adult adjunctive placebo-controlled trials, the most common adverse reactions (≥10% and greater than placebo) were dizziness, headache, nausea, and diplopia. Pediatric adverse reactions are similar to those seen in adult patients.
VIMPAT is a Schedule V controlled substance.
VIMPAT® IS INDICATED FOR THE TREATMENT OF PARTIAL-ONSET
SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER.
As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).
VIMPAT has proven efficacy in children through extrapolation of adult data and a placebo-controlled adjunctive therapy trial.1,2
- The pediatric indication for VIMPAT is based on the principle of extrapolation of efficacy data from adults and is supported by safety and pharmacokinetics data collected in children1
- The efficacy of VIMPAT in pediatric patients 4 years of age and older with partial-onset seizures was confirmed in a placebo-controlled pediatric trial2
VIMPAT offers an established safety and tolerability profile.1,2
- Adverse reactions in pediatric patients were similar to those seen in adult patients. The most common adverse reactions in adults are dizziness, headache, nausea and diplopia
- Pediatric tolerability was demonstrated in open-label trials and a placebo-controlled trial
VIMPAT is available for children in oral solution and tablets with 1:1 dose conversion to meet your patients' needs.2
VIMPAT is covered by most commercial and Medicaid plans, because accessibility and affordability matter.
- >95% of commercial and Medicaid patients have formulary access to VIMPAT1
- Nearly 75% of eligible commercially insured patients paid $20 or less per 30-day supply of VIMPAT with the VIMPAT Savings Program1
- Data on file. UCB, Inc.
- VIMPAT® (lacosamide): US prescribing information. Smyrna (GA): UCB, Inc., November 2017.